You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGenistein
Accession NumberDB01645  (EXPT01582)
TypeSmall Molecule
GroupsInvestigational
DescriptionAn isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines. Additionally, genistein has antihelmintic activity. It has been determined to be the active ingredient in Felmingia vestita, which is a plant traditionally used against worms. It has also been demonstrated to be effective against intestinal parasites such as the common liver fluke, pork trematode and poultry cestode. [Wikipedia] Further, genistein is a phytoestrogen which has selective estrogen receptor modulator properties. It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women. [1] Genistein can be found in food sources such as tofu, fava beans, soybeans, kudzu, and lupin. It is also present in certain cell cultures and medicinal plants. [Wikipedia]
Structure
Thumb
Synonyms
4',5, 7-Trihydroxyisoflavone
5,7,4'-Trihydroxyisoflavone
Genisteol
Genisterin
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PrunetolNot Available
SophoricolNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIDH2M523P0H
CAS number446-72-0
WeightAverage: 270.2369
Monoisotopic: 270.05282343
Chemical FormulaC15H10O5
InChI KeyInChIKey=TZBJGXHYKVUXJN-UHFFFAOYSA-N
InChI
InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H
IUPAC Name
5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
SMILES
OC1=CC=C(C=C1)C1=COC2=C(C(O)=CC(O)=C2)C1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isoflavones. These are polycyclic compounds containing a 2-isoflavene skeleton which bears a ketone group at the C4 carbon atom.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassIsoflavonoids
Sub ClassIsoflav-2-enes
Direct ParentIsoflavones
Alternative Parents
Substituents
  • Hydroxyisoflavonoid
  • Isoflavone
  • Chromone
  • 1-benzopyran
  • Benzopyran
  • Resorcinol
  • Pyranone
  • Phenol
  • Benzenoid
  • Pyran
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous acid
  • Oxacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationCurrently Genistein is being studied in clinical trials as a treatment for prostate cancer.
PharmacodynamicsNot Available
Mechanism of actionGenistein may inhibit cancer cell growth by blocking enzymes required for cell growth. Genistein may decrease cardiovascular risk in postmenopausal women by interacting with the nuclear estrogen receptors to alter the transcription of cell specific genes. In randomized clinical trials, genistein was seen to increase the ratio of nitric oxide to endothelin and improved flow-mediated endothelium dependent vasodilation in healthy postmenopausal women. [1] In addition, genistein may have beneficial effects on glucose metabolism by inhibiting islet tyrosine kinase activity as well as insulin release dependent on glucose and sulfonylurea. [1]
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
SubstrateEnzymesProduct
Genistein
3'-hydroxygenisteinDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
  • Helminthic Microorganisms
  • Parasitic nematodes and other roundworms
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9877
Blood Brain Barrier+0.6785
Caco-2 permeable+0.7002
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.9288
P-glycoprotein inhibitor IINon-inhibitor0.7828
Renal organic cation transporterNon-inhibitor0.9075
CYP450 2C9 substrateNon-substrate0.7672
CYP450 2D6 substrateNon-substrate0.9105
CYP450 3A4 substrateNon-substrate0.6821
CYP450 1A2 substrateInhibitor0.9254
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorInhibitor0.8881
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8009
Ames testNon AMES toxic0.9638
CarcinogenicityNon-carcinogens0.9276
BiodegradationNot ready biodegradable0.8572
Rat acute toxicity3.2988 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9569
hERG inhibition (predictor II)Non-inhibitor0.8917
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point301.5 dec °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.123 mg/mLALOGPS
logP3.04ALOGPS
logP3.08ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)6.55ChemAxon
pKa (Strongest Basic)-5.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area86.99 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity71.68 m3·mol-1ChemAxon
Polarizability26.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)splash10-00di-0321900000-1dd6fcaf99898bd949dfView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-APPI-QQ (API2000) , Positivesplash10-014l-9600000000-04b546320e268d817276View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-APPI-QQ (API2000) , Positivesplash10-00kf-5910000000-7e265d1b4640f882195aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-APPI-QQ (API2000) , Positivesplash10-0v4m-1960000000-7843ec8ae23314f88147View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-APPI-QQ (API2000) , Positivesplash10-00di-0290000000-52ec910b223a3688fbc0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-APPI-QQ (API2000) , Positivesplash10-00di-0190000000-4045f471e10774927fb0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-APPI-QQ (API2000) , Positivesplash10-00di-0090000000-b593f863241cb83cbaa8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-APPI-QQ (API2000) , Positivesplash10-00di-0190000000-0cd8d123608bd54f7214View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) 5V, Positivesplash10-00di-0090000000-9ce354d07dc39313259bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Negativesplash10-001i-0910000000-5eb75a138568fa4ac897View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positivesplash10-0fr6-2920000000-a32f6ae97952bb96de05View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positivesplash10-00di-0290000000-4592d557e739a114cbfaView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITTOF (LCMS-IT-TOF) , Positivesplash10-00di-0090000000-14ae481944ad1a1f7ca0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITTOF (LCMS-IT-TOF) , Negativesplash10-014i-0090030000-a3400b0a77da6983528fView in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

J. Mark Weber, Andreas Constantinou, Paul E. Hessler, “Process of preparing genistein.” U.S. Patent US5554519, issued June, 1994.

US5554519
General References
  1. Crisafulli A, Altavilla D, Marini H, Bitto A, Cucinotta D, Frisina N, Corrado F, D'Anna R, Squadrito G, Adamo EB, Marini R, Romeo A, Cancellieri F, Buemi M, Squadrito F: Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. Menopause. 2005 Mar;12(2):186-92. [PubMed:15772566 ]
  2. Toner E, Brennan GP, Wells K, McGeown JG, Fairweather I: Physiological and morphological effects of genistein against the liver fluke, Fasciola hepatica. Parasitology. 2008 Sep;135(10):1189-203. doi: 10.1017/S0031182008004630. [PubMed:18771609 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Genistein.
AbciximabGenistein may decrease the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Genistein can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Genistein.
AcenocoumarolGenistein may decrease the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Genistein.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Genistein.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Genistein.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Genistein.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Genistein.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Genistein.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Genistein.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Genistein.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Genistein.
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Genistein.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Genistein.
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Genistein.
AncrodGenistein may decrease the anticoagulant activities of Ancrod.
Anthrax immune globulin humanGenistein may increase the thrombogenic activities of Anthrax immune globulin human.
Antithrombin III humanGenistein may decrease the anticoagulant activities of Antithrombin III human.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Genistein.
ArdeparinGenistein may decrease the anticoagulant activities of Ardeparin.
ArgatrobanGenistein may decrease the anticoagulant activities of Argatroban.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Genistein.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Genistein.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Genistein.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Genistein.
AzithromycinThe metabolism of Genistein can be decreased when combined with Azithromycin.
BecaplerminGenistein may decrease the anticoagulant activities of Becaplermin.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Genistein.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Genistein.
BevacizumabBevacizumab may increase the cardiotoxic activities of Genistein.
BivalirudinGenistein may decrease the anticoagulant activities of Bivalirudin.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Genistein.
BortezomibThe metabolism of Genistein can be decreased when combined with Bortezomib.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Genistein.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Genistein.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Genistein.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Genistein.
C1 Esterase Inhibitor (Human)Genistein may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).
C1 Esterase Inhibitor (Recombinant)Genistein may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Genistein.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Genistein.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Genistein.
CaffeineThe metabolism of Genistein can be decreased when combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Genistein.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Genistein.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Genistein.
CarbamazepineThe metabolism of Genistein can be increased when combined with Carbamazepine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Genistein.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Genistein.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Genistein.
CertoparinGenistein may decrease the anticoagulant activities of Certoparin.
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Genistein.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Genistein.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Genistein.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Genistein.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Genistein.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Genistein.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Genistein.
CitalopramThe metabolism of Genistein can be decreased when combined with Citalopram.
Citric AcidGenistein may decrease the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Genistein.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Genistein.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Genistein.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Genistein.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Genistein.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Genistein.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Genistein.
ClotrimazoleThe metabolism of Genistein can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Genistein.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Genistein.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Genistein.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Genistein.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Genistein.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Genistein.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Genistein.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Genistein.
Cyproterone acetateThe serum concentration of Genistein can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Genistein.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Genistein.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Genistein.
DalteparinGenistein may decrease the anticoagulant activities of Dalteparin.
DanaparoidGenistein may decrease the anticoagulant activities of Danaparoid.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Genistein.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Genistein.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Genistein.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Genistein.
DeferasiroxThe serum concentration of Genistein can be increased when it is combined with Deferasirox.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Dehydroepiandrosterone is combined with Genistein.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Genistein.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Genistein.
DesirudinGenistein may decrease the anticoagulant activities of Desirudin.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Genistein.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Genistein.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Genistein.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Genistein.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Genistein.
DextranGenistein may decrease the anticoagulant activities of Dextran.
Dextran 40Genistein may decrease the anticoagulant activities of Dextran 40.
Dextran 70Genistein may decrease the anticoagulant activities of Dextran 70.
Dextran 75Genistein may decrease the anticoagulant activities of Dextran 75.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Genistein.
DicoumarolGenistein may decrease the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Genistein.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Genistein.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Genistein.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Genistein.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Genistein.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Genistein.
DigoxinDigoxin may decrease the cardiotoxic activities of Genistein.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Genistein.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Genistein.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Genistein.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Genistein.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Genistein.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Genistein.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Genistein.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Genistein.
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Genistein.
Edetic AcidGenistein may decrease the anticoagulant activities of Edetic Acid.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Genistein.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Genistein.
EnoxaparinGenistein may decrease the anticoagulant activities of Enoxaparin.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Genistein.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Genistein.
EquilinThe serum concentration of Equilin can be increased when it is combined with Genistein.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Genistein.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Genistein.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Genistein.
EstriolThe serum concentration of Estriol can be increased when it is combined with Genistein.
EstroneThe serum concentration of Estrone can be increased when it is combined with Genistein.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Genistein.
Ethyl biscoumacetateGenistein may decrease the anticoagulant activities of Ethyl biscoumacetate.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Genistein.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Genistein.
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Genistein.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Genistein.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Genistein.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Genistein.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Genistein.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Genistein.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Genistein.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Genistein.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Genistein.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Genistein.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Genistein.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Genistein.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Genistein.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Genistein.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Genistein.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Genistein.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Genistein.
FluvoxamineThe metabolism of Genistein can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumGenistein may decrease the anticoagulant activities of Fondaparinux sodium.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Genistein.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Genistein.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Genistein.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Genistein.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Genistein.
HeparinGenistein may decrease the anticoagulant activities of Heparin.
HirulogGenistein may decrease the anticoagulant activities of Hirulog.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Genistein.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Genistein.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Genistein.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Genistein.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Genistein.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Genistein.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Genistein.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Genistein.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Genistein.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Genistein.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Genistein.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Genistein.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Genistein.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Genistein.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Genistein.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Genistein.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Genistein.
LenalidomideGenistein may increase the thrombogenic activities of Lenalidomide.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Genistein.
LepirudinGenistein may decrease the anticoagulant activities of Lepirudin.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Genistein.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Genistein.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Genistein.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Genistein.
LidocaineThe metabolism of Genistein can be decreased when combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Genistein.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Genistein.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Genistein.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Genistein.
LosartanThe serum concentration of Losartan can be increased when it is combined with Genistein.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Genistein.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Genistein.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Genistein.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Genistein.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Genistein.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Genistein.
MexiletineThe metabolism of Genistein can be decreased when combined with Mexiletine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Genistein.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Genistein.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Genistein.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Genistein.
MorphineThe serum concentration of Morphine can be increased when it is combined with Genistein.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Genistein.
NadololThe serum concentration of Nadolol can be increased when it is combined with Genistein.
NadroparinGenistein may decrease the anticoagulant activities of Nadroparin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Genistein.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Genistein.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Genistein.
NevirapineThe metabolism of Genistein can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Genistein.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Genistein.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Genistein.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Genistein.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Genistein.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Genistein.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Genistein.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Genistein.
OsimertinibThe serum concentration of Genistein can be decreased when it is combined with Osimertinib.
OspemifeneThe risk or severity of adverse effects can be increased when Genistein is combined with Ospemifene.
OtamixabanGenistein may decrease the anticoagulant activities of Otamixaban.
OuabainOuabain may decrease the cardiotoxic activities of Genistein.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Genistein.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Genistein.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Genistein.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Genistein.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Genistein.
Peginterferon alfa-2bThe serum concentration of Genistein can be increased when it is combined with Peginterferon alfa-2b.
Pentosan PolysulfateGenistein may decrease the anticoagulant activities of Pentosan Polysulfate.
PhenindioneGenistein may decrease the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Genistein.
PhenobarbitalThe metabolism of Genistein can be increased when combined with Phenobarbital.
PhenprocoumonGenistein may decrease the anticoagulant activities of Phenprocoumon.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Genistein.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Genistein.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Genistein.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Genistein.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Genistein.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Genistein.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Genistein.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Genistein.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Genistein.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Genistein.
PrimidoneThe metabolism of Genistein can be increased when combined with Primidone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Genistein.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Genistein.
Protein CGenistein may decrease the anticoagulant activities of Protein C.
ProtocatechualdehydeGenistein may decrease the anticoagulant activities of Protocatechualdehyde.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Genistein.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Genistein.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Genistein.
QuinineThe serum concentration of Quinine can be increased when it is combined with Genistein.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Genistein.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Genistein.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Genistein.
ReviparinGenistein may decrease the anticoagulant activities of Reviparin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Genistein.
RifampicinThe metabolism of Genistein can be increased when combined with Rifampicin.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Genistein.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Genistein.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Genistein.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Genistein.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Genistein.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Genistein.
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Genistein.
RopiniroleThe metabolism of Genistein can be decreased when combined with Ropinirole.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Genistein.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Genistein.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Genistein.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Genistein.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Genistein.
SimeprevirThe metabolism of Genistein can be decreased when combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Genistein.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Genistein.
Somatropin recombinantThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Genistein.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Genistein.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Genistein.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Genistein.
SulodexideGenistein may decrease the anticoagulant activities of Sulodexide.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Genistein.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Genistein.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Genistein.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Genistein.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Genistein.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Genistein.
TenofovirThe metabolism of Genistein can be decreased when combined with Tenofovir.
TeriflunomideThe serum concentration of Genistein can be decreased when it is combined with Teriflunomide.
ThalidomideGenistein may increase the thrombogenic activities of Thalidomide.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Genistein.
TheophyllineThe metabolism of Genistein can be decreased when combined with Theophylline.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Genistein.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Genistein.
TiclopidineThe metabolism of Genistein can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Genistein.
TipranavirGenistein may increase the dermatologic adverse activities of Tipranavir.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Genistein.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Genistein.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Genistein.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Genistein.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Genistein.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Genistein.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Genistein.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Genistein.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Genistein.
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Genistein.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Genistein.
VemurafenibThe serum concentration of Genistein can be increased when it is combined with Vemurafenib.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Genistein.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Genistein.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Genistein.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Genistein.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Genistein.
Vitamin CThe serum concentration of Genistein can be increased when it is combined with Vitamin C.
WarfarinGenistein may decrease the anticoagulant activities of Warfarin.
XimelagatranGenistein may decrease the anticoagulant activities of Ximelagatran.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Genistein.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560). Isoform beta-cx lacks ligand binding ability and has no or only very low ere binding activity resulting in the loss of ligand-dependent transactivation ability. DNA-binding by...
Gene Name:
ESR2
Uniprot ID:
Q92731
Molecular Weight:
59215.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Molecular Weight:
174383.88 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Signal transducer activity
Specific Function:
Non-receptor protein-tyrosine kinase that regulates reorganization of the actin cytoskeleton, cell polarization, cell migration, adhesion, spreading and bone remodeling. Plays a role in the regulation of the humoral immune response, and is required for normal levels of marginal B-cells in the spleen and normal migration of splenic B-cells. Required for normal macrophage polarization and migrati...
Gene Name:
PTK2B
Uniprot ID:
Q14289
Molecular Weight:
115873.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transcription coactivator activity
Specific Function:
Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Involved in the coactivation of different nuclear receptors, such as for steroids (PGR, GR and ER), retinoids (RXRs), thyroid hormone (TRs) and prostanoids (PPARs). Also involved in coactivation mediated by STAT3, STAT5A, STAT5B and STAT6 transcription...
Gene Name:
NCOA1
Uniprot ID:
Q15788
Molecular Weight:
156755.44 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transcription coactivator activity
Specific Function:
Transcriptional coactivator for steroid receptors and nuclear receptors. Coactivator of the steroid binding domain (AF-2) but not of the modulating N-terminal domain (AF-1). Required with NCOA1 to control energy balance between white and brown adipose tissues. Critical regulator of glucose metabolism regulation, acts as RORA coactivator to specifically modulate G6PC expression. Involved in the ...
Gene Name:
NCOA2
Uniprot ID:
Q15596
Molecular Weight:
159155.645 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Hu M, Krausz K, Chen J, Ge X, Li J, Gelboin HL, Gonzalez FJ: Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab Dispos. 2003 Jul;31(7):924-31. [PubMed:12814970 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Identical protein binding
Specific Function:
Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.
Gene Name:
TTR
Uniprot ID:
P02766
Molecular Weight:
15886.88 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Castro AF, Altenberg GA: Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem Pharmacol. 1997 Jan 10;53(1):89-93. [PubMed:8960067 ]
  2. Versantvoort CH, Rhodes T, Twentyman PR: Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Br J Cancer. 1996 Dec;74(12):1949-54. [PubMed:8980395 ]
  3. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Pec MK, Aguirre A, Fernandez JJ, Souto ML, Dorta JF, Villar J: Dehydrothyrsiferol does not modulate multidrug resistance-associated protein 1 resistance: a functional screening system for MRP1 substrates. Int J Mol Med. 2002 Nov;10(5):605-8. [PubMed:12373300 ]
  2. Nguyen H, Zhang S, Morris ME: Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci. 2003 Feb;92(2):250-7. [PubMed:12532374 ]
  3. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. [PubMed:14511674 ]
  4. Versantvoort CH, Rhodes T, Twentyman PR: Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Br J Cancer. 1996 Dec;74(12):1949-54. [PubMed:8980395 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Imai Y, Tsukahara S, Asada S, Sugimoto Y: Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res. 2004 Jun 15;64(12):4346-52. [PubMed:15205350 ]
  2. Zhang S, Yang X, Morris ME: Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol. 2004 May;65(5):1208-16. [PubMed:15102949 ]
  3. Perez M, Real R, Mendoza G, Merino G, Prieto JG, Alvarez AI: Milk secretion of nitrofurantoin, as a specific BCRP/ABCG2 substrate, in assaf sheep: modulation by isoflavones. J Vet Pharmacol Ther. 2009 Oct;32(5):498-502. doi: 10.1111/j.1365-2885.2008.01050.x. [PubMed:19754918 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23